Table 1 PICOS statement for the inclusion and exclusion criteria

Study population

Patients with high-volume metastatic hormone-sensitive prostate cancer, regardless of age, sex, ethnic group or disease status

Any not listed in the inclusion criteria

Intervention

Docetaxel + ADT

Any not listed in the inclusion criteria

Comparator

Abiraterone + prednisone + ADT

ADT alone

Any not listed in the inclusion criteria

Outcome measures

Clinical efficacy outcomes Safety outcomes

Any not listed in the inclusion criteria

Study design

Randomised clinical trials (RCTs)

Editorials OR Notes OR Comments OR Letters OR Case reports OR Pharmacokinetic studies OR Epidemiology studies

Restrictions

Full-text published manuscripts in English or Chinese

Year limitation: up to Nov 2017

Duplicates

Not full-text published manuscripts Non-English or non-Chinese studies